See the DrugPatentWatch profile for ozempic

Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, prescribed for the treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with diabetes and established cardiovascular disease [1]. GLP-1 receptor agonists, such as Ozempic, work by mimicking the functions of natural hormones in your body to control blood sugar levels [2].

Regarding appetite and portion sizes, Ozempic has been shown to impact users in several ways [1]:

1. Decreased Appetite: Ozempic can lead to a decrease in appetite, which may result in weight loss. This is because GLP-1 receptor agonists, like Ozempic, stimulate the area of the brain that regulates appetite and satiety, leading to a reduced desire to eat [1][3].
2. Slowed Gastric Emptying: Ozempic slows down the rate at which the stomach empties after eating, which can contribute to a feeling of fullness and potentially reduce portion sizes [1][3].
3. Weight Loss: As a result of decreased appetite and slowed gastric emptying, many users experience weight loss while taking Ozempic [1][3].

It is essential to consult a healthcare professional for personalized advice on managing appetite, portion sizes, and medication use.

Sources:

[1] DrugPatentWatch.com. (n.d.). Ozempic (semaglutide) - DrugPatentWatch. Retrieved from https://www.drugpatentwatch.com/drugs/ozempic

[2] U.S. Food and Drug Administration. (2017, December 5). FDA approves once-weekly Ozempic (semaglutide) injection for type 2 diabetes. FDA. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-once-weekly-ozempic-semaglutide-injection-type-2-diabetes

[3] National Institute of Diabetes and Digestive and Kidney Diseases. (2017, April). Glucagon-Like Peptide-1 Receptor Agonists. NIDDK. Retrieved from https://www.niddk.nih.gov/-/media/Files/Diabetes/PDFs/glp1ra-508.pdf